^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    FGFR2b inhibitor

    Related drugs:
    Apply
    Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101) (NCT05052801)
    Phase 3
    Amgen
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    03/07/2022
    Primary completion :
    08/18/2025
    Completion :
    08/18/2025
    FGFR2
    |
    FGFR2 overexpression • FGFR2b overexpression
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
    Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102) (NCT05111626)
    Phase 3
    Amgen
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    03/14/2022
    Primary completion :
    09/26/2026
    Completion :
    09/26/2026
    FGFR2
    |
    FGFR2 overexpression • FGFR2b overexpression
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
    A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (NCT05267470)
    Phase 1
    Amgen
    Active, not recruiting
    Last update posted :
    05/10/2024
    Initiation :
    03/29/2022
    Primary completion :
    04/09/2024
    Completion :
    05/31/2024
    KRAS • NTRK
    |
    KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)
    A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (NCT03694522)
    Phase 2
    Five Prime Therapeutics, Inc.
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    09/14/2018
    Primary completion :
    09/23/2020
    Completion :
    05/13/2022
    FGFR2
    |
    FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
    A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer (NCT05913115)
    Phase 1
    Amgen
    Completed
    Last update posted :
    06/22/2023
    Initiation :
    06/12/2017
    Primary completion :
    06/19/2018
    Completion :
    06/19/2018
    FGFR2
    |
    bemarituzumab (AMG 552)